CLX reports its next quarterly results on August 3 with the analyst community shifting more negative in the final days before the print — a meaningful development given short positioning that was already elevated heading into the failed July 31 report date.
Analysts have moved predominantly in one direction recently. Jefferies downgraded CLX to Hold from Buy on July 28, cutting its target from $125 to $98 — the most significant single move in the pre-earnings window. JP Morgan and Evercore both trimmed targets while holding negative ratings, Evercore moving from $110 to $98. Of the recent changes, only UBS nudged its target slightly higher ($96 to $100), and even that came with a Neutral rating. The consensus now sits at Hold, with just one Buy against fourteen Hold ratings and a mean target of $102.35 — roughly 7% above the current price of $95.53. That gap looks modest relative to the downward pressure on estimates, and the directional message from the Street is clear: analysts are becoming more selective on the risk/reward case.
Bears already had a firm foothold before the analyst moves landed. Short interest runs at 9.8% of the free float, a level that has climbed roughly 23% over the past month and remains near recent highs. Days to cover sits just under five. The borrow market offers no friction: availability of 280% means roughly three shares are available to borrow for every one on loan, and the cost to borrow has eased further to 0.46% — down about 8% on the week. Bears can add exposure cheaply and easily. Options positioning has stayed elevated into the August date, with the put/call ratio at 0.80 — about one standard deviation above the 20-day average of 0.71, and approaching the 52-week high of 0.94 reached earlier this year.
The lone contrarian data point worth noting is insider activity. Director Pierre Breber bought 5,000 shares in early May at $85.82, a purchase worth roughly $429,000 — the only meaningful buy in the recent history and scored at significance 3 (above routine). That said, subsequent insider activity has been small-scale selling from operating executives at prices well above current levels, suggesting the stock has drifted lower since that purchase was made.
The August 3 print will test whether the company can offer any credible path to recovering volume momentum — because at current prices, flat or negative guidance would likely validate the growing consensus that the post-pandemic normalisation story has further to run.
See the live data behind this article on ORTEX.
Open CLX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
